Kwality Pharma Q1 FY27 Earnings Call Transcript

FY27 Revenue Guidance: Management expects total sales revenue to exceed INR700 crores for FY27.
FY27 EBITDA Margin Guidance: EBITDA margins are projected to be between 26% to 27%.
Long-Term Revenue Target: The company has built an internal model targeting INR1,500 crores in revenue by FY2030, implying a year-on-year growth rate of 25% to 30%.
Plant Operations: The company has five operational units: biologicals, general facility, oncology, cephalosporin, and beta lactam. A sixth unit, a hormone plant, is scheduled to commence operations by November 2026.
Product Registrations: The company is consistently registering new molecules every quarter, with an expectation of 6-7 new product registrations per quarter going forward. Each registration contributes roughly INR1.5-2 million in yearly sales.

FY27 Capex: A total capital expenditure of INR185-190 crores is planned for FY27.
Capex Breakdown:
INR70 crores allocated for the hormone plant.
INR50 crores for oncology expansion.
INR25-30 crores for bioequivalence studies.
INR20 crores for working capital.
INR10-15 crores for biosimilar R&D.
Biosimilar Capex: An additional INR150 crores in capex is required for three biosimilars, to be spent between Q3 FY28 and Q4 FY29.
Funding: Capex is currently being funded from internal accruals and an unused extended loan facility. There are no immediate plans to utilize significant debt.

Erythropoietin: Pre-clinical studies are complete. Permission to conduct clinical trials has been received. Trials are expected to begin by November or December 2026. PK/PD studies will be conducted first, with clinical closure expected by October or November 2027. Domestic (Indian) sales are expected to commence immediately after trial completion, with international sales targeted before the end of calendar year 2027. The company has already begun filing in 10-12 geographies.
Revenue Projection for Erythropoietin:
FY28: INR80-100 crores (primarily domestic market).
FY29: INR200-250 crores (including international sales).
Keytruda (Pembrolizumab): CDSCO and Gene Modification Authority approvals have been received to conduct stability batches and pre-clinical studies. Pre-clinical studies are scheduled to begin by December 2026 and finish by March 2027. Clinical trials are expected to take 1-1.5 years. Commercialization is targeted before the end of calendar year 2028, aligning with patent expiry, aiming for a first-wave launch.
Bioequivalence Program: Focuses on three complex injectables:

1. Amphotericin B Liposomal: Targeted to be the second generic.

2. Octreotide LAR: Targeted to be the first generic in ~70% of markets.

3. Leuprolide 45mg: Targeted to be the first generic in 75-80% of markets.

BE studies for Amphotericin B and Octreotide are expected to finish by April-May 2027 (Q1 FY28). Leuprolide studies are expected to finish by Q2 FY28.
Revenue Projection from BE Program:
FY28: INR80-100 crores.
FY29: INR400-500 crores.

Oncology Segment: Contributed 20% of revenue in Q1 FY27, down from 26% previously. The contribution is expected to be between 25-30% for the full year, with significant registrations expected by Q4 FY27. Oncology revenue for FY27 is guided at INR100-110 crores.
Geographic Mix:
35-40% of revenue is currently from the Rest of World (ROW) market.
Strong registration activity noted in LATAM (Mexico, Colombia, Chile) and MENA regions (Algeria, Morocco, Tunisia).
New submissions have been made in Saudi Arabia and other GCC countries, with revenues expected from these regions by Q3 FY27.
By FY30, 10-15% of sales are expected to come from the European market.
Gross Margins: Were 53% in Q1 FY27, down from 56-57% in the previous quarter. Management expects ideal gross margins to settle at 47% as the business scales, with the current higher margin attributed to a 35-40% revenue share from the ROW market.

General Facility: 75-80% utilized. An expansion is planned to add 20% more capacity.
Oncology Facility: 75-80% utilized. An expansion is underway to add 45-50% more capacity.
Cephalosporin & Beta Lactam Facilities: Roughly 20-25% utilized.
Biologics Facility: A 500-liter bioreactor is installed but awaits CDSCO approval; currently used for clinical batches.

Debtor Days: Elevated at 208 days in FY26 due to geopolitical disruptions. Management is targeting a reduction to 165-170 days by end of FY27 and a normalized level of 155-160 days thereafter.
Receivables: Expected to be around INR300 crores by end-FY27 against revenue of ~INR700 crores, representing ~40% of revenue.

Relationship with Deepak Bansal & SD Biopharmaceuticals: Described as a business association. Deepak Bansal helped develop sales in European and LATAM markets. Mana Pharma (European company) has invested in Kwality's dossiers. SD Pharma is Mana Pharma's entity in India that purchases from Kwality for supply to countries like Venezuela, Colombia, and Mexico.
Kaler Biopharma: An entity promoted by Deepak Bansal and Ramesh Arora for a proposed oncology plant project. The project is currently on hold, and the land involved may be sold or subject to another arrangement.
Algerian JV: A joint venture arrangement is being discussed for a fill-finish plant in Algeria. The counterparty would invest in the plant, and Kwality would contribute technology and clinical data for 3-4 biosimilar molecules in exchange for equity. Similar arrangements are being explored in Mexico and other LATAM countries.

Auditor Appointment: The company plans to appoint KPMG as its global auditor. An agreement has been filed, and the appointment is expected in Q3 or Q4 FY27, pending necessary software upgrades and system preparations.
Promoter Stake: There are no immediate plans for promoters to increase their stake via warrants or open market purchases, though it may be considered in the future.

Management cited the following risk factors:

Timeline Risk: Delays in receiving product registrations from various Ministries of Health could affect sales targets.
Execution Risk: The need for directors to remain grounded and not get carried away by small successes.
Operational Risk: Management stated there is no significant risk related to product quality, facilities, or team, citing successful past audits from CDSCO (7 times in 3 years) and frequent external audits from international regulators.